dry eye

Testing at point of care for improved patient satisfaction, re-treatment ratesAfter spending a few months testing for dry eye and treating the tear film before doing preoperative measurements, the re-treatment rate dropped from 11% to 3%.
Yet another new revolution in ocular surface imagingDuring the past two decades, an incredible number of imaging technologies have been developed for eye diseases, both for diagnosis and follow-up.
Don’t let bad beauty habits suck the fun out of Halloween
Don’t let bad beauty habits suck the fun out of HalloweenWhether your Halloween makeup plans are glamorous or ghoulish, incorrect makeup practices are frightful for eye health.
How vaping affects the ocular surfaceElectronic cigarettes (e-cigarettes) are devices designed to deliver nicotine in a solution rather than smoke without tobacco combustion. Perceived by consumers as a safer alternative to conventional cigarettes, e-cigarettes are aggressively marketed as lifestyle-choice consumables.
New eye drop assistant helps drive complianceAs ODs, we are fully aware of the challenge patient compliance with prescribed eye drops. To assuage the battle of compliance, eye drop manufacturers are assiduously working to devise drug delivery systems that reduce or eliminate patients’ engagement in the instillation of their prescribed therapy. But until ODs no longer use eye drops, drops remain our primary mode of drug delivery.
The changing dry eye dynamicTo understand how far we have come, you must remember where we started.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Using neurostimulation to treat dry eye
Using neurostimulation to treat dry eyeNeurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
Numbers transform dry eye treatment for symptomatic, asymptomatic patientsAdding objective point-of-care dry eye diagnostics to your practice has deep, measurable effects, including more accurate and consistent IOL power calculations.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.